Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Monte Rosa Therapeutics, Inc. (GLUE) vs Kura Oncology, Inc. (KURA)

Monte Rosa Therapeutics, Inc. and Kura Oncology, Inc. are both Biotechnology companies. Monte Rosa Therapeutics, Inc. and Kura Oncology, Inc. are of similar size ($999.9M and $977.7M). Kura Oncology, Inc. has the higher net margin (−384.3% vs −560.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Monte Rosa Therapeutics, Inc. leads on 10 and Kura Oncology, Inc. on 5.

Valuation

Metric GLUE KURA Biotechnology median
P/E n/m n/m 7.88
P/S 41.58 12.45 11.47
P/B 2.45 19.85 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 19.96 5.86 10.73
Earnings yield (14.95%) (31.15%) (28.84%)
Free cash flow yield (2.69%) (12.21%) (23.03%)

Profitability

Metric GLUE KURA Biotechnology median
Gross margin 100.00% 99.35% 65.16%
Operating margin (633.04%) (411.90%) 0.00%
Net margin (560.85%) (384.30%) 0.00%
Free cash flow margin (111.66%) (152.06%) 0.00%
Return on equity (42.66%) (167.71%) (57.72%)
Return on assets (30.67%) (46.73%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GLUE KURA Biotechnology median
Revenue growth (TTM) (83.86%) — 5.64%
EPS growth (last fiscal year) 53.06% (57.43%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GLUE KURA Biotechnology median
Debt to equity 0.00 0.20 0.00
Current ratio 10.58 4.73 4.73
Net debt to EBITDA 8.22 2.11 0.96

Dividend

Metric GLUE KURA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric GLUE KURA Biotechnology median
Market cap 999.87m 977.67m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack